ইউরোপীয় ইউনিয়ন -
রোমানীয় -
EMA (European Medicines Agency)
visudyne
cheplapharm arzneimittel gmbh - verteporfina - myopia, degenerative; macular degeneration - oftalmologice - visudyne este indicat pentru tratamentul:adulți cu exudativa (umeda) degenerescenta maculara legata de varsta (amd), cu precădere clasic neovascularizație coroidiană subfoveală (cnv) sau;adulți cu neovascularizație coroidiană subfoveală secundară unei miopii patologice.
মোল্দাভিয়া -
রোমানীয় -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
tricortin 1000 12 mg + 1 mg/2 ml soluţie injectabilă
fidia farmaceutici s.p.a. - phospholipidum + cyanocobalaminum - soluţie injectabilă - 12 mg + 1 mg/2 ml
মোল্দাভিয়া -
রোমানীয় -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
tricortin 1000 12 mg/1 mg/2 ml soluţie injectabilă
fidia farmaceutici s.p.a. - phospholipidum + cyanocobalaminum - soluţie injectabilă - 12 mg/1 mg/2 ml
ইউরোপীয় ইউনিয়ন -
রোমানীয় -
EMA (European Medicines Agency)
lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologice - lucentis este indicat la adulți pentru:tratamentul de forma neovasculară (umedă) degenerescenta maculara legata de varsta (amd)tratamentul de insuficiență vizuale din cauza neovascularizație coroidiană (cnv)tratamentul de insuficiență vizuale din cauza edemului macular diabetic (emd)tratamentul tulburărilor vizuale datorită edemului macular secundar ocluzia venei retiniene (filiala rvo sau centrale rvo).
ইউরোপীয় ইউনিয়ন -
রোমানীয় -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
ইউরোপীয় ইউনিয়ন -
রোমানীয় -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ইউরোপীয় ইউনিয়ন -
রোমানীয় -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
মোল্দাভিয়া -
রোমানীয় -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
lucentis solutie injectabila 10 mg/ml
novartis pharma ag - solutie injectabila - 10 mg/ml
মোল্দাভিয়া -
রোমানীয় -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
lexacin 500 mg comprimate filmate
technolog sap - levofloxacinum - comprimate filmate - 500 mg
মোল্দাভিয়া -
রোমানীয় -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
lexacin 250 mg comprimate filmate
technolog sap - levofloxacinum - comprimate filmate - 250 mg